新型联合纳米药物脂质体，用于治疗乳腺癌。

IF 3 4区医学 Q2 CHEMISTRY, APPLIED

Journal of microencapsulation Pub Date : 2025-06-01 Epub Date: 2025-04-04 DOI:10.1080/02652048.2025.2487031

Mohamed Attia, David Hill, Cheng Shu Chaw, Amal Ali Elkordy

{"title":"新型联合纳米药物脂质体，用于治疗乳腺癌。","authors":"Mohamed Attia, David Hill, Cheng Shu Chaw, Amal Ali Elkordy","doi":"10.1080/02652048.2025.2487031","DOIUrl":null,"url":null,"abstract":"Aims: Doxorubicin (DOX), a potent chemotherapeutic, is a commonly prescribed treatment for breast cancer, but is limited by severe organ toxicity. Therefore, more effective therapies are required. This study developed a novel DOX-liposomes (LipDOX-ALA-AA) co-loaded with alpha-lipoic-acid (ALA) and ascorbic-acid (AA) to enhance antineoplastic effect.Methods: Liposomes were fabricated using a microfluidic-system with a DSPClipid:Cholesterol ratio of 1:1 and a flow rate ratio of 5:1. Liposomes were investigated using various-techniques such-as dynamic light scattering to measure liposomes' size and charge; and UV-spectroscopy to determine DOX-encapsulation-efficiency, EE. Cytotoxicity assays used various cell-lines.Results: Data revealed that LipDOX-ALA-AA had diameter of 79.0 ± 0.3 nm, with narrow size distribution, and zeta-potential of -4.0 ± 1.2. DOX-EE exceeded 95%, drug load was 0.5 mg/105.5 mg total content, drug release followed a biphasic pattern. Cytotoxicity assay showed activity (p < 0.05) against breast cancer cell-lines with reduced nephrotoxicity compared to Doxosome.Conclusion: This novel formulation (LipDOX-ALA-AA) offers a promise in breast cancer therapy.","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"368-391"},"PeriodicalIF":3.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Novel combinational nanomedicines, liposomes, to tackle breast cancer.\",\"authors\":\"Mohamed Attia, David Hill, Cheng Shu Chaw, Amal Ali Elkordy\",\"doi\":\"10.1080/02652048.2025.2487031\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aims: Doxorubicin (DOX), a potent chemotherapeutic, is a commonly prescribed treatment for breast cancer, but is limited by severe organ toxicity. Therefore, more effective therapies are required. This study developed a novel DOX-liposomes (LipDOX-ALA-AA) co-loaded with alpha-lipoic-acid (ALA) and ascorbic-acid (AA) to enhance antineoplastic effect.Methods: Liposomes were fabricated using a microfluidic-system with a DSPClipid:Cholesterol ratio of 1:1 and a flow rate ratio of 5:1. Liposomes were investigated using various-techniques such-as dynamic light scattering to measure liposomes' size and charge; and UV-spectroscopy to determine DOX-encapsulation-efficiency, EE. Cytotoxicity assays used various cell-lines.Results: Data revealed that LipDOX-ALA-AA had diameter of 79.0 ± 0.3 nm, with narrow size distribution, and zeta-potential of -4.0 ± 1.2. DOX-EE exceeded 95%, drug load was 0.5 mg/105.5 mg total content, drug release followed a biphasic pattern. Cytotoxicity assay showed activity (p < 0.05) against breast cancer cell-lines with reduced nephrotoxicity compared to Doxosome.Conclusion: This novel formulation (LipDOX-ALA-AA) offers a promise in breast cancer therapy.\",\"PeriodicalId\":16391,\"journal\":{\"name\":\"Journal of microencapsulation\",\"volume\":\" \",\"pages\":\"368-391\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of microencapsulation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/02652048.2025.2487031\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, APPLIED\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of microencapsulation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02652048.2025.2487031","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CHEMISTRY, APPLIED","Score":null,"Total":0}

引用次数: 0

摘要

目的：多柔比星（DOX）是一种有效的化疗药物，是乳腺癌的常用处方治疗方法，但由于严重的器官毒性而受到限制。因此，需要更有效的治疗方法。本研究开发了一种新型的脂质体（LipDOX-ALA-AA），该脂质体与α -硫辛酸（ALA）和抗坏血酸（AA）共负载，以增强抗肿瘤作用。方法：采用DSPClipid：胆固醇比为1:1，流速比为5:1的微流控系统制备脂质体。利用各种技术对脂质体进行了研究，如动态光散射测量脂质体的大小和电荷；紫外光谱法测定dox包封效率、EE。细胞毒性试验使用各种细胞系。结果：LipDOX-ALA-AA粒径为79.0±0.3 nm，粒径分布窄，ζ电位为-4.0±1.2；DOX-EE含量超过95%，载药量为0.5 mg/105.5 mg，药物释放呈双相模式。结论：这种新型制剂（LipDOX-ALA-AA）在乳腺癌治疗中具有良好的应用前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Novel combinational nanomedicines, liposomes, to tackle breast cancer.

Aims: Doxorubicin (DOX), a potent chemotherapeutic, is a commonly prescribed treatment for breast cancer, but is limited by severe organ toxicity. Therefore, more effective therapies are required. This study developed a novel DOX-liposomes (LipDOX-ALA-AA) co-loaded with alpha-lipoic-acid (ALA) and ascorbic-acid (AA) to enhance antineoplastic effect.

Methods: Liposomes were fabricated using a microfluidic-system with a DSPClipid:Cholesterol ratio of 1:1 and a flow rate ratio of 5:1. Liposomes were investigated using various-techniques such-as dynamic light scattering to measure liposomes' size and charge; and UV-spectroscopy to determine DOX-encapsulation-efficiency, EE. Cytotoxicity assays used various cell-lines.

Results: Data revealed that LipDOX-ALA-AA had diameter of 79.0 ± 0.3 nm, with narrow size distribution, and zeta-potential of -4.0 ± 1.2. DOX-EE exceeded 95%, drug load was 0.5 mg/105.5 mg total content, drug release followed a biphasic pattern. Cytotoxicity assay showed activity (p < 0.05) against breast cancer cell-lines with reduced nephrotoxicity compared to Doxosome.

Conclusion: This novel formulation (LipDOX-ALA-AA) offers a promise in breast cancer therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of microencapsulation 工程技术-工程：化工

CiteScore

6.30

自引率

2.60%

发文量

审稿时长

3 months

期刊介绍： The Journal of Microencapsulation is a well-established, peer-reviewed journal dedicated to the publication of original research findings related to the preparation, properties and uses of individually encapsulated novel small particles, as well as significant improvements to tried-and-tested techniques relevant to micro and nano particles and their use in a wide variety of industrial, engineering, pharmaceutical, biotechnology and research applications. Its scope extends beyond conventional microcapsules to all other small particulate systems such as self assembling structures that involve preparative manipulation. The journal covers: Chemistry of encapsulation materials Physics of release through the capsule wall and/or desorption from carrier Techniques of preparation, content and storage Many uses to which microcapsules are put.